 CohBar, Inc. is an interesting early-clinical-stage biotechnology company developing mitochondrial-based therapeutics for treating chronic and age-related diseases including nonalcoholic steatohepatitis and obesity, amongst others. CohBars pipeline consists of the lead compound, CB4211, which is in a Phase 1b and Phase 1a1b for NASH and Obesity, respectively, and four other pre-clinical mitochondrial-based programs. 